)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
InnoCare Pharma (9969) investor relations material
InnoCare Pharma Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Status Update summary9 Oct, 2025
Strategic collaboration and licensing agreement
Zenas acquires global development and commercialization rights for orelabrutinib in multiple sclerosis and other non-oncology indications, plus two preclinical autoimmune candidates, from InnoCare Pharma.
The agreement includes an upfront payment of up to $100 million, milestone payments, up to 7 million Zenas shares, and total potential transaction value exceeding $2 billion, with tiered royalties up to 10% on net sales.
Zenas gains exclusive global rights for orelabrutinib in MS and non-oncology areas outside Greater China and Southeast Asia, while InnoCare retains oncology and regional rights.
Clinical development and pipeline updates
Orelabrutinib is in a global Phase III trial for primary progressive MS (PPMS), with a secondary progressive MS (SPMS) trial to start in Q1 2026; both trials approved by FDA and EMA.
Phase II data showed orelabrutinib significantly reduced new brain lesions and maintained efficacy through 96 weeks in relapsing-remitting MS.
Two preclinical assets, an oral IL-17AA/AF inhibitor and a brain-penetrating oral TYK2 inhibitor, are expected to enter clinical trials in 2026.
Zenas' pipeline also includes obexelimab, with Phase III data in IgG4-RD expected end of 2025 and Phase II data in relapsing MS in Q4 2025.
Strategic rationale and future outlook
The collaboration aims to accelerate orelabrutinib's global development and maximize its commercial value, especially in progressive MS where treatment options are limited.
Both companies emphasize the potential for orelabrutinib and the new preclinical assets to become best-in-class therapies for autoimmune diseases.
Zenas plans to leverage its late-stage development expertise to efficiently advance orelabrutinib and other pipeline assets.
Detail key value drivers for the $2B deal
What differentiates orelabrutinib from other BTK inhibitors for MS?
How do orelabrutinib and obexelimab MS strategies align?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next InnoCare Pharma earnings date
Q3 202510 Nov, 2025
Next InnoCare Pharma earnings date
Q3 202510 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
InnoCare Pharma Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for cancer and autoimmune diseases. The company leverages its research and development capabilities to advance targeted therapies, including small molecules and biologics. InnoCare’s pipeline includes investigational treatments addressing hematologic malignancies, solid tumors, and chronic immune-related conditions. The company is headquartered in Beijing, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage